Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment according to CAP Grading System: Clinical Usefulness and Limitations.

ABSTRACT:

Background

Neoadjuvant treatment (NAT) is increasingly employed for pancreatic ductal adenocarcinoma (PDAC), necessitating reliable methods to assess tumor response. The College of American Pathologists (CAP) grading system is widely used to predict chemo-responsiveness and survival, but consensus on the most effective grading system and treatment regimen remains elusive.

Patients and methods

This retrospective study included 462 patients with PDAC who underwent resection after NAT between 2009 and 2023. Survival outcomes were analyzed on the basis of CAP grades, and factors influencing favorable tumor responses were identified.

Results

Patients with CAP grades 0 and 1 showed significantly better overall survival (OS) and disease-free survival (DFS) than those with CA

SUBMITTER: Choi GW 

PROVIDER: S-EPMC12589204 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature